Jørgen Bjerggaard Jensen
15
1
4
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.7%
1 terminated/withdrawn out of 15 trials
90.0%
+3.5% vs industry average
27%
4 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
NORTH-REG Dwell-Time Study
Role: lead
Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC
Role: lead
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit
Role: lead
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
Role: lead
Complete Local Response to Neoadjuvant Chemotherapy in Patients With Muscle Invasive Bladder Cancer Evaluated by 15O-H2O PET/MR
Role: lead
En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer
Role: lead
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
Role: lead
Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer
Role: lead
Endo-GIA Versus Endowrist Stapler in Intracorporeal Urinary Diversion in Robotic Assisted Radical Cystectomy
Role: lead
Early Versus Late FDG-PET/CT in Bladder Cancer
Role: lead
MOdified Urinary Conduit to Lower Strictures After radIcal Cystectomy
Role: lead
Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
Role: lead
Photodynamic Diagnosis (PDD) in Flexible Cystoscopy
Role: lead
Lung Protective Ventilation During Robotic Assisted Prostatectomy
Role: lead
Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy
Role: lead
All 15 trials loaded